Ovarian and Breast Cancer
We recommend
Targeting HER2 is Clinically Meaningful Even with Its Low Expression
Distinguishing HER2 receptor expression status on the surface of breast cancer tumor cells as simply positive or negative is now proving insufficient. Ultimately, it can lead to the non-administration of effective targeted therapy. What do we actually know about the “gray zone” between HER2 positivity and negativity?
Trastuzumab Deruxtecan in Patients with HER2+ Metastatic Breast Cancer
Last year, results of studies published in the Lancet journal demonstrated a significant clinical…
Current Sequence of Treatment for Metastatic HER2+ Breast Cancer
In September 2023, experts from Miami Cancer Institute published their consensus statement on the…
Articles on this topic
Does olaparib improve overall survival in patients with recurrent ovarian cancer and BRCA mutation?
Olaparib, a poly(ADP-ribose) polymerase (PARP) enzyme inhibitor, in tablet form is indicated,…
Frequency of Mutations in Genes Predisposing to Ovarian Cancer in the Czech Population
The authors of a Czech study evaluating the occurrence of mutations in tumor-predisposing…
Current Indication Criteria for Testing Mutations in BRCA1 and BRCA2 Genes in Breast and Ovarian Cancer
Testing the mutation status of the BRCA1/2 genes can be beneficial for prevention, and in the…
How to Communicate and Receive an Oncological Diagnosis
Communicating the truth to a patient about their health condition does not have a very long tradition...
Overall Survival and Tolerance of Olaparib in the OlympiAD Study – Results of Extended Follow-up
Olaparib provides women with metastatic breast cancer with a germline BRCA mutation, who have…
Maintenance treatment with oral olaparib in women with BRCA1/2 mutation and relapsed ovarian cancer
In a phase III study published in the journal Lancet Oncology, data on the effectiveness of…
Benefit of Maintenance Therapy with Olaparib in Newly Diagnosed Advanced Ovarian Cancer
The SOLO-1 study evaluated whether the use of the PARP inhibitor olaparib in the maintenance…
Subscribe
Most read on this topic
Journal on this topic
Related topic
Interesting links
Most read on this topic
- Current Indication Criteria for Testing Mutations in BRCA1 and BRCA2 Genes in Breast and Ovarian Cancer
- Does olaparib improve overall survival in patients with recurrent ovarian cancer and BRCA mutation?
- Targeting HER2 is Clinically Meaningful Even with Its Low Expression
- Frequency of Mutations in Genes Predisposing to Ovarian Cancer in the Czech Population
- Current Sequence of Treatment for Metastatic HER2+ Breast Cancer
- Maintenance treatment with oral olaparib in women with BRCA1/2 mutation and relapsed ovarian cancer
Journal on this topic
Related topic
Interesting links